p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease.
We evaluated p186Her2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease. We identified six patients with recurrent vulvar Paget's disease in our archives. The number of recurrences ranged from 1 to 11 over a time period of 1-168 months. Recurrences were evaluated immunohistochemically for p185Her2 overexpression with the HercepTest and for HER2 oncogene amplification with fluorescence in situ hybridization. p185Her2 overexpression was scored as 3 in two patients, as 2 in two patients, and as 1 in two patients. All patients with scores 2 and 3 showed HER2 oncogene amplification. Overexpression of p185Her2 and HER2 oncogene amplification appears to be common in recurrent vulvar Paget's disease.
Reich
Olaf
O
Department of Obstetrics and Gynecology, Medical University of Graz, Austria. olaf.reich@meduni-graz.at
Liegl
Bernadette
B
Tamussino
Karl
K
Regauer
Sigrid
S
D000368:Aged; D005260:Female; D005784:Gene Amplification; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010145:Paget Disease, Extramammary / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics*; D014846:Vulvar Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*
D018719:Erb-b2 Receptor Tyrosine Kinases